rplC T460C Identified as a Dominant Mutation in Linezolid-Resistant Mycobacterium tuberculosis Strains

Beckert P, Hillemann D, Kohl T, Kalinowski J, Richter E, Niemann S, Feuerriegel S (2012)
Antimicrobial Agents and Chemotherapy 56(5): 2743-2745.

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ; ;
Abstract
The ribosomal L3 protein was identified as a novel target in linezolid (LZD)-resistant Mycobacterium tuberculosis strains. Next-generation sequencing confirmed rplC T460C as the sole mutation in an LZD-resistant M. tuberculosis H37Rv strain selected in vitro. Sequencing analysis revealed the rplC T460C mutation in eight further LZD-resistant isolates (three in vitro-selected mutants and five patient isolates, including isolates from three different patients that developed LZD resistance during treatment) but in none of the susceptible control strains (n = 84).
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Beckert P, Hillemann D, Kohl T, et al. rplC T460C Identified as a Dominant Mutation in Linezolid-Resistant Mycobacterium tuberculosis Strains. Antimicrobial Agents and Chemotherapy. 2012;56(5):2743-2745.
Beckert, P., Hillemann, D., Kohl, T., Kalinowski, J., Richter, E., Niemann, S., & Feuerriegel, S. (2012). rplC T460C Identified as a Dominant Mutation in Linezolid-Resistant Mycobacterium tuberculosis Strains. Antimicrobial Agents and Chemotherapy, 56(5), 2743-2745.
Beckert, P., Hillemann, D., Kohl, T., Kalinowski, J., Richter, E., Niemann, S., and Feuerriegel, S. (2012). rplC T460C Identified as a Dominant Mutation in Linezolid-Resistant Mycobacterium tuberculosis Strains. Antimicrobial Agents and Chemotherapy 56, 2743-2745.
Beckert, P., et al., 2012. rplC T460C Identified as a Dominant Mutation in Linezolid-Resistant Mycobacterium tuberculosis Strains. Antimicrobial Agents and Chemotherapy, 56(5), p 2743-2745.
P. Beckert, et al., “rplC T460C Identified as a Dominant Mutation in Linezolid-Resistant Mycobacterium tuberculosis Strains”, Antimicrobial Agents and Chemotherapy, vol. 56, 2012, pp. 2743-2745.
Beckert, P., Hillemann, D., Kohl, T., Kalinowski, J., Richter, E., Niemann, S., Feuerriegel, S.: rplC T460C Identified as a Dominant Mutation in Linezolid-Resistant Mycobacterium tuberculosis Strains. Antimicrobial Agents and Chemotherapy. 56, 2743-2745 (2012).
Beckert, Patrick, Hillemann, Doris, Kohl, Thomas, Kalinowski, Jörn, Richter, Elvira, Niemann, Stefan, and Feuerriegel, Silke. “rplC T460C Identified as a Dominant Mutation in Linezolid-Resistant Mycobacterium tuberculosis Strains”. Antimicrobial Agents and Chemotherapy 56.5 (2012): 2743-2745.
This data publication is cited in the following publications:
This publication cites the following data publications:

7 Citations in Europe PMC

Data provided by Europe PubMed Central.

Mutations in the bacterial ribosomal protein l3 and their association with antibiotic resistance.
Klitgaard RN, Ntokou E, Norgaard K, Biltoft D, Hansen LH, Trædholm NM, Kongsted J, Vester B., Antimicrob. Agents Chemother. 59(6), 2015
PMID: 25845869
In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis.
Zhang M, Sala C, Dhar N, Vocat A, Sambandamurthy VK, Sharma S, Marriner G, Balasubramanian V, Cole ST., Antimicrob. Agents Chemother. 58(6), 2014
PMID: 24663022
Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis.
Balasubramanian V, Solapure S, Iyer H, Ghosh A, Sharma S, Kaur P, Deepthi R, Subbulakshmi V, Ramya V, Ramachandran V, Balganesh M, Wright L, Melnick D, Butler SL, Sambandamurthy VK., Antimicrob. Agents Chemother. 58(1), 2014
PMID: 24189255
From multidrug-resistant to extensively drug-resistant tuberculosis in Lisbon, Portugal: the stepwise mode of resistance acquisition.
Perdigao J, Macedo R, Silva C, Machado D, Couto I, Viveiros M, Jordao L, Portugal I., J. Antimicrob. Chemother. 68(1), 2013
PMID: 23054995
Linezolid for treatment of chronic extensively drug-resistant tuberculosis.
Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE 3rd., N. Engl. J. Med. 367(16), 2012
PMID: 23075177

13 References

Data provided by Europe PubMed Central.

Oxazolidinones: activity, mode of action, and mechanism of resistance.
Bozdogan B, Appelbaum PC., Int. J. Antimicrob. Agents 23(2), 2004
PMID: 15013035
In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants.
Hillemann D, Rusch-Gerdes S, Richter E., Antimicrob. Agents Chemother. 52(2), 2008
PMID: 18070973
Extensively drug-resistant tuberculosis: current challenges and threats.
Jain A, Mondal R., FEMS Immunol. Med. Microbiol. 53(2), 2008
PMID: 18479439
The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria.
Leach KL, Swaney SM, Colca JR, McDonald WG, Blinn JR, Thomasco LM, Gadwood RC, Shinabarger D, Xiong L, Mankin AS., Mol. Cell 26(3), 2007
PMID: 17499045
Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin.
Locke JB, Hilgers M, Shaw KJ., Antimicrob. Agents Chemother. 53(12), 2009
PMID: 19805557
Strategies against multidrug-resistant tuberculosis.
Loddenkemper R, Sagebiel D, Brendel A., Eur Respir J Suppl 36(), 2002
PMID: 12168749
A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.
Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, Ortmann J, Girardi E, Hoffmann H, Besozzi G, Bevilacqua N, Kirsten D, Centis R, Lange C; TBNET Study Group, Hurevich H, Skrahin A, Muetterlein R, Schaberg T, Eberhardt R, Flick H, de Roux A, Hamm M, Hang H, Hannemann P, Hillemann D, Kretz B, Laumanns C, Paulick A, Pletz MW, Rau M, Schaudt C, Matteelli A, Spanevello A, Toungoussova O, D'Ambrosio L, De Lorenzo S, Troupioti P, De Iaco G, Gualano A, De Mori P, Lauria FN, Ferrara G, Cirillo D, Janssens JP., Eur. Respir. J. 34(2), 2009
PMID: 19282348
Current and novel antibiotics against resistant Gram-positive bacteria.
Perez F, Salata RA, Bonomo RA., Infect Drug Resist 1(), 2008
PMID: 21694878
First linezolid-resistant clinical isolates of Mycobacterium tuberculosis.
Richter E, Rusch-Gerdes S, Hillemann D., Antimicrob. Agents Chemother. 51(4), 2007
PMID: 17242139
Linezolid in the treatment of multidrug-resistant tuberculosis.
Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S., Clin. Infect. Dis. 50(1), 2010
PMID: 19947856
Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus.
Wolter N, Smith AM, Farrell DJ, Schaffner W, Moore M, Whitney CG, Jorgensen JH, Klugman KP., Antimicrob. Agents Chemother. 49(8), 2005
PMID: 16048983

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 22371899
PubMed | Europe PMC

Search this title in

Google Scholar